NEW YORK (GenomeWeb News) – Empire Genomics said today that it has acquired the exclusive license to a genomic biomarker from Emory University for the development of a molecular diagnostic test for determining which therapies may be most suitable for specific patients with multiple myeloma.

A phase II biomarker-driven clinical trial is being conducted using the technology to validate its ability to predict outcomes of new generations of drugs for the blood cell cancer, Empire Genomics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.